Journal of Thoracic Oncology

Papers
(The H4-Index of Journal of Thoracic Oncology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Comment on “MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC”1003
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?373
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response283
Board of Directors276
PP01.25 Exploring the Impact of Socioeconomic and Geographic Factors on Immunotherapy Discontinuation and Success in Northern Ontario: A Retrospective, Single-Center Cohort Study255
Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples232
Serum microRNAs are Associated with Treatment Response and Disease Progression in Limited Stage Small Cell Lung Cancer223
FBXO11 Mediates PARP Inhibitor Resistance in Small-Cell Lung Cancer213
PPD01.03: Real World Data On Lung Cancer Detection In A High-Risk Population In A Colombian Insurance Company190
PP01.21: Evaluating the Accuracy & Reproducibility of ChatGPT Models in Answering Patient’s Lung Cancer Queries179
EP.08D.06 Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center Psmanalysis167
P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study154
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study149
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib145
P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols139
OA16.03 Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY138
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients132
EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation116
EP.15B.04 High-Fiber Intake Predicts Overall Survival in Lung Cancer Patients - Real-World Analyses113
EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study113
MA11.13 Peripheral T-Cell Receptor Repertoire Differentiates a Typical Progression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy110
MA01.04 AFT-46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer107
P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer105
EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer102
EP.13D.07 Impact of Antiemetic Steroid Use on Survival in Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors and Chemotherapy Combination101
P2.04A.07 Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)97
P1.01A.01 The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439)94
P3.03I.08 Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations- Anin Vitrostudy93
EP.03F.05 A Dose-Effect Relationship of a Novel Bronchoscopy Guided Endobronchial Radiofrequency Ablation for Peripheral Lung Tumors92
MA07.09 Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy91
EP.11A.05 Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience90
MA04.05 An Evolution and Expanding Engagement to Excel in Lung Cancer Screening90
EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study89
EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study87
EP.08F.18 Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database82
P1.01C.04 Key Stakeholder Priorities on Embedding Smoking Cessation Into Lung Cancer Screening: National Australian Consensus Workshop81
EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold80
P2.17B.03 Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits80
MA18.09 Comparing Efficient Lung Cancer Screening Strategies for Black and White Americans80
EP.04A.16 Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study79
EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma - Case Report76
P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival75
P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab75
P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US74
EP.16A.01 Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey74
EP.07A.08 Modified Periareolar Incision for Uniportal Segmentectomy74
OA01.06 A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer72
EP.12A.39 MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review.69
P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma68
Rethinking Biomarkers for Combination Chemoimmunotherapy67
P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy67
Lung Cancer in Japan66
Current and Future Treatment Options in the Management of Stage III NSCLC66
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study66
OA04.06 The Global Landscape of Lung Squamous Cell Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer Incidence in 202065
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion63
Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort63
Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells63
PP01.172 It's Never Too Late To Quit61
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis59
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study59
0.063610076904297